Skip to main content
Signal8

Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study

$DWTXPress releaseMay 18, 2026, 8:45 AM ET

Dogwood Therapeutics announced the commencement of a 12-week open-label extension study for its lead asset Halneuron in chemotherapy-induced neuropathic pain (CINP). The decision follows a positive interim assessment of the ongoing Phase 2b double-blinded study, which showed a treatment effect versus placebo in 97 patients and a dropout rate under 5%.

Key figures

Drug Name
Halneuron
Phase Of Trial
Phase 2b
Dropout rate
<5%
Target sample size
210-240
Interim patient count
97
Mean symptom duration
5 years

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.